Celebrex Has No Apparent MI Signal At 200 Mg Or Less, FDAer Graham Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The drug safety officer's meta-analysis suggests that Celebrex and Bextra can both be safely marketed at low doses, but Vioxx poses a risk at both the 25 mg and 50 mg doses. At committee meeting, Graham discusses results of two unpublished studies, which he says he was initially told by FDA not to present.
You may also be interested in...
FDA To Act On COX-2 Committee Input Within "Next Few Weeks"
In remarks to the Arthritis Drugs/Drug Safety & Risk Management advisory committee meeting, CDER Acting Director Galson says the agency will take "rapid" action on the panel's recommendations.
FDA To Act On COX-2 Committee Input Within "Next Few Weeks"
In remarks to the Arthritis Drugs/Drug Safety & Risk Management advisory committee meeting, CDER Acting Director Galson says the agency will take "rapid" action on the panel's recommendations.
FDA's Graham To Present Overview At COX-2 Advisory Committee Meeting
Office of Drug Safety Director for Science & Medicine David Graham is scheduled to present an "epidemiological overview" on Feb. 16, day one of the three-day meeting. Senate Finance Committee Chairman Charles Grassley is concerned that FDA has forbidden Graham from discussing certain data.